Segment Information	12 Months Ended
Jun. 30, 2025
Disclosure of operating segments [abstract]
Segment Information	Note 6. Segment Information The Group operates in one industry and two geographical areas, those being the biotechnology and healthcare industry and Australia and United States, respectively. The Group is focused primarily on developing novel therapeutic products based on targeting Vascular Endothelial Growth Factors (VEGF) C, D and R3. The chief financial officer regularly reviews entity wide information that is compliant with International Financial Reporting Standards. There is only one segment for segment reporting purposes, and the information reviewed by the chief financial officer for the purpose of resources allocation and performance assessment is the same as the information presented in the consolidated financial statements. The Group’s only revenue stream in the current and previous financial year is royalty income generated from licenses granted in respect of the Group’s intellectual property that are unrelated to the Group’s core business and the development novel therapeutic products based on targeting Vascular Endothelial Growth Factors (VEGF) C, D and R3. These licenses are primarily used by third‑party licensees for research purposes. All of the royalty income of US$25 thousand (2024: US$125thousand 2023:US$108 thousand) was generated from customers based outside of Australia. The Group does not have any major customers. All equipment is located in Australia and United States.

Segment Information

12 Months Ended

Jun. 30, 2025

Disclosure of operating segments [abstract]

Note 6. Segment Information

The Group operates in one industry and two geographical areas, those being the biotechnology and healthcare industry and Australia and United States, respectively.

The Group is focused primarily on developing novel therapeutic products based on targeting Vascular Endothelial Growth Factors (VEGF) C, D and R3.

The chief financial officer regularly reviews entity wide information that is compliant with International Financial Reporting Standards. There is only one segment for segment reporting purposes, and the information reviewed by the chief financial officer for the purpose of resources allocation and performance assessment is the same as the information presented in the consolidated financial statements.

The Group’s only revenue stream in the current and previous financial year is royalty income generated from licenses granted in respect of the Group’s intellectual property that are unrelated to the Group’s core business and the development novel therapeutic products based on targeting Vascular Endothelial Growth Factors (VEGF) C, D and R3. These licenses are primarily used by third‑party licensees for research purposes. All of the royalty income of US$25 thousand (2024: US$125thousand 2023:US$108 thousand) was generated from customers based outside of Australia. The Group does not have any major customers. All equipment is located in Australia and United States.